XML 25 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 14,310,862 $ 46,329,359
Short-term investments 130,982,913 206,669,397
Prepaid expenses and other current assets 5,393,665 50,130,481
Prepaid expenses and other current assets from affiliated entities 20,432 375,227
Total current assets 153,113,100 315,242,680
Fixed assets, net 4,960,986 7,727,997
Investments in affiliated entity 2,780,287 2,007,142
Intangible assets, net 0 2,129,861
Goodwill 0 10,513,371
Operating lease right-of-use assets 9,491,735 10,228,207
Other assets 605,315 684,044
Total assets 170,951,423 348,533,302
Current liabilities:    
Accrued clinical trial expenses 2,365,382 10,594,073
Operating lease liability 2,406,522 2,803,973
Grant funding liability 87,489 2,475,031
Grant funding liability from affiliated entities 21,918 87,673
Convertible senior notes 16,770,654 0
Total current liabilities 42,570,228 96,868,074
Convertible senior notes 0 16,614,840
Operating lease liability, net of current portion 11,032,066 12,655,586
Deferred tax liabilities 0 32,046
Total liabilities 53,602,294 126,170,546
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2023 and 2022 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2023 and 2022, issued and outstanding: 22,793,075 at December 31, 2023 and 21,090,938 at December 31, 2022 [1] 22,792 21,090
Additional paid-in capital 1,740,954,074 1,710,888,191
Accumulated deficit (1,622,965,136) (1,487,847,784)
Accumulated other comprehensive loss (662,601) (698,741)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 117,349,129 222,362,756
Total liabilities and stockholders’ equity 170,951,423 348,533,302
Nonrelated Party    
Current assets:    
Accounts receivable 0 1,701,726
Current liabilities:    
Accounts payable and accrued expenses 19,847,744 79,686,885
Related Party    
Current assets:    
Accounts receivable 2,405,228 10,036,490
Current liabilities:    
Accounts payable and accrued expenses $ 1,070,519 $ 1,220,439
[1]
(1) The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock. Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024. Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.